Haptoglobin and Iron in Parkinson's Disease (HPPD)

Haptoglobin Phenotype and Smoking: Effects on Iron Levels in Parkinson's Disease

This is a case/control epidemiology study to identify what are the iron-metabolism abnormalities in Parkinson's disease (PD) patients, and risk factors relevant to PD predisposition.

Study Overview

• Status: Completed
• Conditions: Parkinson's Disease

Detailed Description

A total of 342 participants, 100 PD patients and 242 age- and gender matched controls, were included in the study. All study participants were seen for one study visit in the morning at one of two Bastyr University Clinics in the Seattle area. Study participants were fasting at the time of the visit. During the study visit, participants donated a blood sample for the blood tests and complete an epidemiology questionnaire.

A subset of 51 of the study participant who were seen for the visit at Bastyr University, underwent brain scan and Magnetic Resonance Imaging (MRI), at the University of Washington Department of Radiology. The MRI part of the study aims at estimating brain iron levels.

• Study Type: Observational
• Enrollment (Actual): 342

Contacts and Locations

Study Locations

• United States
  • California
    • San Diego, California, United States, 92093
      • University of California
  • Washington
    • Kenmore, Washington, United States, 98028
      • Bastyr University Research Institute
    • Seattle, Washington, United States, 98195
      • University of Washington

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 92 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Parkinson's disease patients will be included in the study if they received a diagnosis of Parkinson's disease that meets the United Kingdom Brain Bank (UKBB) clinical criteria of Parkinson's disease diagnosis.

Control participants will be included in the study if free of neurodegenerative diseases.

A subset of the study participants (60 total) receive Magnetic Resonance Imaging to estimate brain iron

Description

Inclusion Criteria for the Controls, for the blood draw and epidemiology visit:

• Volunteers should be of age between 52 and 82 years of age, males of females.

Exclusion Criteria for the Controls:

• presence of a neurodegenerative disease,
• presence of active cancer under treatment,
• HIV sero-positivity, Hepatitis B, C, of A sero-positivity
• rheumatoid arthritis
• recent blood donation (less than three months before the visit).
• fever at the time of the visit

Inclusion Criteria for the Parkinson's disease patients:

Diagnosis of Parkinson's disease (UKBB clinical criteria).

Exclusion criteria for the Parkinson's disease patients, for the blood draw and epidemiology visit:

• Presence of other neurodegenerative diseases, apart for Parkinson's disease
• two or more family members with Parkinson's disease
• presence of active cancer under treatment
• HIV sero-positivity, Hepatitis B, C, of A sero-positivity
• rheumatoid arthritis
• recent blood donation (less than three months before the visit).
• fever at the time of the visit

Exclusion criteria for the Magnetic Resonance Imaging:

• presence in the body of a ferro-magnetic metallic foreign object such as, but not limited to:
• a cardiac pacemaker
• aneurism clip
• neuro-stimulator
• surgical clip
• artificial limb or joint
• orthopedic items, such as screws, nails, pins, rods,
• any metallic foreign body from a previous injury, bullets, shrapnels, metal slivers.
• exclusion criteria for MRI is also the presence of claustrophobia

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
PD; 100 PD patients were patients diagnosed with Parkinson's disease
Controls; 242 Controls were subjects free of neurodegenerative diseases, matched by age and gender to the PD patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Iron metabolism differences between PD patients and controls	Iron metabolism will be measured by testing for serum iron and iron-binding proteins, and by estimating brain iron by MRI. Serum iron parameters that will be measured include total serum iron, iron-binding proteins such as transferrin and ferritin, and tests related to iron metabolism: transferrin % saturation, unsaturated iron binding capacity, soluble transferrin receptor, complete blood count, hemoglobin, uric acid, haptoglobin, haptoglobin phenotype. Differences in serum iron parameters, and brain iron levels, between PD patients and controls will be calculated.	Up to 7 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Environmental factors affecting PD risk and gene-environment interactions	Questionnaire data will be analyzed to identify risk factors for PD by comparing lifestyle and dietary patterns from questionnaire between PD cases and controls. Interaction between haptoglobin phenotype and tobacco smoking on PD risk will be calculated, as well as interaction between haptoglobin phenotype and environmental factors such as tobacco smoking and diet on serum iron and brain iron levels.	recruitment until January 2016

Collaborators and Investigators

• Sponsor: Bastyr University
• Collaborators: University of Washington
• Investigators: Principal Investigator: Paola Costa-Mallen, PhD, Bastyr University

Publications and helpful links

General Publications

• Costa-Mallen P, Checkoway H, Zabeti A, Edenfield MJ, Swanson PD, Longstreth WT Jr, Franklin GM, Smith-Weller T, Sadrzadeh SM. The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2008 Mar 5;147B(2):216-22. doi: 10.1002/ajmg.b.30593.

Study record dates

Study Major Dates

• Study Start: February 1, 2013
• Primary Completion (Actual): June 1, 2016
• Study Completion (Actual): June 1, 2016

Study Registration Dates

• First Submitted: April 15, 2015
• First Submitted That Met QC Criteria: April 17, 2015
• First Posted (Estimate): April 22, 2015

Study Record Updates

• Last Update Posted (Estimate): November 29, 2016
• Last Update Submitted That Met QC Criteria: November 28, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Keywords: MRI; risk factors; Iron metabolism; haptoglobin phenotype
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease
• Other Study ID Numbers: 12A-1330